Point72 Hong Kong LTD 89bio, Inc. Transaction History

Point72 Hong Kong LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.09 - $4.02 $2,386 - $4,590	-1,142 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $3,939 - $17,118	1,142 New	1,142 $4,000
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $4,476 - $7,196	-257 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $5,196 - $6,869	257 New	257 $6,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $11,533 - $13,983	-498 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $12,121 - $19,332	498 New	498 $13,000

166

111M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $508M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.